Placeholder Banner

ASCO Publishes New "Value Framework" for Cancer Treatment Options

June 24, 2015
On Monday, the American Society of Clinical Oncology (ASCO) published "A Framework to Assess the Value of Cancer Treatment Options” in the Journal of Clinical Oncology intended to 'assess the value of new cancer therapies based on treatment benefits, toxicities, and costs.'

The framework, developed by the ASCO Value in Cancer Care Task Force, is intended to 'ultimately serve as the basis for user-friendly, standardized tools that physicians can use with their patients to discuss the relative value of new cancer therapies as compared with established treatments.'

BIO is in the process of studying ASCO’s Value Framework and we will likely have more to say once we get a better understanding of the proposals.

We share the goal of ensuring that patients maintain access to high-quality, individualized care. Any decision-making tool should present patients and their providers with all available treatment options so they can make informed decisions about their best course of treatment.

More than 80% of survival gains in cancer are attributable to new treatments and medicines; caution must be taken not to exclude the possibility that a new medicine may be “just what the doctor ordered” for that patient whose life hangs in the balance.

Furthermore, we believe that any tool should preserve the complex clinical decision-making that goes on within the context of the provider/patient relationship — taking into account the provider’s judgement and expertise and the patient’s priorities.

ASCO will be accepting public comments through August 21, 2015.